EL7.AI
StocksMedium•22 September 2026•
1 min read

Viking Therapeutics Gains on Positive VK2735 Weight Loss Study Results

Key Facts

1Viking Therapeutics reported 22% placebo-adjusted weight loss at week 33 following weekly dosing of VK2735.
2Results showed up to 97% of weight loss was maintained when transitioning to every-other-week dosing.
3The drug demonstrated excellent tolerability with gastrointestinal adverse event rates similar to placebo.

Amid the intensifying race for innovative obesity treatments, Viking Therapeutics has announced positive results from its Phase 2 study of VK2735. The data revealed a 22% placebo-adjusted weight loss after 33 weeks of weekly dosing, with no observed plateau in efficacy. Furthermore, the drug demonstrated excellent tolerability, with gastrointestinal adverse event rates similar to the placebo group, strengthening the company's position in this high-growth sector.

According to technical reports, participants maintained up to 97% of their weight loss when transitioning to an every-other-week dosing regimen, addressing long-term treatment adherence challenges. These clinical results position VKTX as a serious competitor to major pharmaceutical firms in the weight-loss market. Per market data, VKTX shares closed at $30.11 on September 21, 2026, having reached a day high of $30.7.

Traders should monitor the stock's performance relative to its recent range of $28.41 to $30.7 (as of close September 21, 2026). With no immediate biotech-related catalysts in the upcoming economic calendar, market focus will likely remain on further regulatory updates regarding VK2735. These results represent a pivotal step for Viking Therapeutics in validating monthly and bi-weekly maintenance dosing schedules.